{"article_title": "CVS Health chooses single PCSK9 inhibitor for its commercial formularies", "article_keywords": ["pcsk9", "statins", "commercial", "cvs", "chooses", "high", "single", "right", "health", "treatment", "members", "cholesterol", "formularies", "inhibitor", "patients", "possible"], "article_url": "http://www.drugstorenews.com/article/cvs-health-chooses-single-pcsk-inhibitor-its-commercial-formularies", "article_text": "WOONSOCKET, R.I. \u2014 After taking time to compare the two PCSK9 inhibitors approved by the Food and Drug Administration this year, CVS Health has determined that its CVS/caremark will list Amgen\u2019s Repatha (evolocumab) over Regeneron Pharmaceuticals\u2019 Praluent. (alirocumab).\n\nCVS Health said its Pharmacy and Therapeutics Committee evaluated both drugs thoroughly, determining that they were therapeutically equivalent, which was corroborated by board-certified cardiology and endocrinology specialists.\n\n\u201cCVS Health is committed to providing high-quality medications for our clients and their members at the lowest possible cost,\u201d CVS Health\u2019s EVP and chief medical officer Troyen Brennan said. \u201cWe have determined that choosing a single PCSK9 inhibitor for our commercial formularies allows us to get the best price possible for clients and preserves our commitment to deliver the best care available.\u201d\n\nThe company also added that, though PCKS9 inhibitors are a promising new treatment for high cholesterol, CVS/caremark\u2019s approach begins with statins. This is not a new approach from the company which, in August following both drugs\u2019 approvals, called for a reassessment of guidelines concerning high cholesterol in the Journal of American Medicine, arguing that it should be clearly defined which patients should receive the treatment, which could cost up to $14,600.\n\n\u201cWe believe patients should have access to the right medication, at the right time and for the right reason,\u201d Brennan said. \u201cWe anticipate that for most members with high cholesterol, statins will remain the standard of care, given long-standing evidence that they prevent heart disease and the fact that they are extremely cost-effective.\u201d", "article_metadata": {"sailthru.image.thumb": "http://www.drugstorenews.com/sites/drugstorenews.com/files/field_thumbnail_image/11-2015/CVS_Corporate_headquarters_main.jpg", "sailthru.author": "David Salazar", "description": "CVS Health has opted to only offer one of the two new PCSK9 inhibitors on its CVS/caremark commercial formularies.", "og": {"image": {"width": 200, "identifier": "http://www.drugstorenews.com/sites/drugstorenews.com/files/field_medium_image/11-2015/CVS_Corporate_headquarters_main.jpg", "height": 200}, "type": "article", "title": "CVS Health chooses single PCSK9 inhibitor for its commercial formularies"}, "twitter": {"description": "CVS Health has opted to only offer one of the two new PCSK9 inhibitors on its CVS/caremark commercial formularies.", "title": "CVS Health chooses single PCSK9 inhibitor for its commercial formularies", "url": "http://www.drugstorenews.com/article/cvs-health-chooses-single-pcsk-inhibitor-its-commercial-formularies", "image": "http://www.drugstorenews.com/sites/drugstorenews.com/files/field_main_image/2015-11/CVS_Corporate_headquarters_main.jpg", "site": "@drugstorenews", "card": "summary"}, "sailthru.date": "2015-11-23 01:01:00", "sailthru.title": "CVS Health chooses single PCSK9 inhibitor for its commercial formularies", "keywords": "cvs health, praluent, repatha, pcsk9-inhibitors", "google-site-verification": "qD-DLdnS9RBbjYJ-MITi4cSvUByohsoX4WClEJJuv7I", "sailthru.image.full": "http://www.drugstorenews.com/sites/drugstorenews.com/files/field_main_image/2015-11/CVS_Corporate_headquarters_main.jpg", "viewport": "width=device-width, initial-scale=1.0"}, "article_summary": "\u201cWe anticipate that for most members with high cholesterol, statins will remain the standard of care, given long-standing evidence that they prevent heart disease and the fact that they are extremely cost-effective.\u201d\n\u201cCVS Health is committed to providing high-quality medications for our clients and their members at the lowest possible cost,\u201d CVS Health\u2019s EVP and chief medical officer Troyen Brennan said.\n\u201cWe believe patients should have access to the right medication, at the right time and for the right reason,\u201d Brennan said.\nCVS Health said its Pharmacy and Therapeutics Committee evaluated both drugs thoroughly, determining that they were therapeutically equivalent, which was corroborated by board-certified cardiology and endocrinology specialists.\nWOONSOCKET, R.I. \u2014 After taking time to compare the two PCSK9 inhibitors approved by the Food and Drug Administration this year, CVS Health has determined that its CVS/caremark will list Amgen\u2019s Repatha (evolocumab) over Regeneron Pharmaceuticals\u2019 Praluent."}